TY - JOUR
T1 - Association between an Alzheimer's Disease-Related Index and APOE ε4 Gene Dose
AU - Schraml, Frank
AU - Chen, Kewei
AU - Ayutyanont, Napatkamon
AU - Auttawut, Roontiva
AU - Langbaum, Jessica B.S.
AU - Lee, Wendy
AU - Liu, Xiaofen
AU - Bandy, Dan
AU - Reeder, Stephanie Q.
AU - Alexander, Gene E.
AU - Caselli, Richard J.
AU - Fleisher, Adam S.
AU - Reiman, Eric M.
PY - 2013/6/26
Y1 - 2013/6/26
N2 - Background:We introduced a hypometabolic convergence index (HCI) to characterize in a single measurement the extent to which a person's fluorodeoxyglucose positron emission tomogram (FDG PET) corresponds to that in Alzheimer's disease (AD). Apolipoprotein E ε4 (APOE ε4) gene dose is associated with three levels of risk for late-onset AD. We explored the association between gene dose and HCI in cognitively normal ε4 homozygotes, heterozygotes, and non-carriers.Methods:An algorithm was used to characterize and compare AD-related HCIs in cognitively normal individuals, including 36 ε4 homozygotes, 46 heterozygotes, and 78 non-carriers.Results:These three groups differed significantly in their HCIs (ANOVA, p = 0.004), and there was a significant association between HCIs and gene dose (linear trend, p = 0.001).Conclusions:The HCI is associated with three levels of genetic risk for late-onset AD. This supports the possibility of using a single FDG PET measurement to help in the preclinical detection and tracking of AD.
AB - Background:We introduced a hypometabolic convergence index (HCI) to characterize in a single measurement the extent to which a person's fluorodeoxyglucose positron emission tomogram (FDG PET) corresponds to that in Alzheimer's disease (AD). Apolipoprotein E ε4 (APOE ε4) gene dose is associated with three levels of risk for late-onset AD. We explored the association between gene dose and HCI in cognitively normal ε4 homozygotes, heterozygotes, and non-carriers.Methods:An algorithm was used to characterize and compare AD-related HCIs in cognitively normal individuals, including 36 ε4 homozygotes, 46 heterozygotes, and 78 non-carriers.Results:These three groups differed significantly in their HCIs (ANOVA, p = 0.004), and there was a significant association between HCIs and gene dose (linear trend, p = 0.001).Conclusions:The HCI is associated with three levels of genetic risk for late-onset AD. This supports the possibility of using a single FDG PET measurement to help in the preclinical detection and tracking of AD.
UR - https://www.scopus.com/pages/publications/84879472461
UR - https://www.scopus.com/pages/publications/84879472461#tab=citedBy
U2 - 10.1371/journal.pone.0067163
DO - 10.1371/journal.pone.0067163
M3 - Article
C2 - 23840615
AN - SCOPUS:84879472461
SN - 1932-6203
VL - 8
JO - PloS one
JF - PloS one
IS - 6
M1 - e67163
ER -